Drug Profile
Research programme: anti-cancer therapeutics - Halozyme
Alternative Names: HTI-1511; PEG NME8058; PEG NME8062; PEG-ADA2; PEG-ADA2-E182T; PEG-ADA2-K374D; PEG-ADA2-R222Q-S265N; PEGylated adenosine deaminase 2Latest Information Update: 12 Nov 2019
Price :
$50
*
At a glance
- Originator Halozyme Therapeutics
- Class Auristatins; Enzymes; Immunoconjugates
- Mechanism of Action Adenosine deaminase stimulants; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- Discontinued Cholangiocarcinoma; Chronic lymphocytic leukaemia; Colorectal cancer; Lung cancer; Pancreatic cancer; Solid tumours
Most Recent Events
- 04 Nov 2019 Discontinued - Preclinical for Cholangiocarcinoma in USA (unspecified route) due to organisational restructuring
- 04 Nov 2019 Discontinued - Preclinical for Chronic lymphocytic leukaemia in USA (unspecified route) due to organisational restructuring
- 04 Nov 2019 Discontinued - Preclinical for Colorectal cancer in USA (unspecified route) due to organisational restructuring